Bullous systemic lupus erythematosus successfully treated with rituximab

Christopher D. Lowe, Catherine A. Brahe, Brian Philip Green, Thomas K. Lam, Jon H. Meyerle

Research output: Contribution to journalArticle

Abstract

Bullous systemic lupus erythematosus (BSLE) is a rare complication of systemic lupus erythematosus (SLE) characterized by cutaneous vesicles and bullae with a primarily neutrophilic infiltrate on histopathology. Bullous SLE is a heterogeneous disease without pathognomonic clinical features, making the diagnosis and differentiation from other blistering diseases challenging. We present the case of a single patient with SLE in whom 3 different clinical appearances of BSLE manifested over 5 years. The cutaneous eruption dramatically improved with rituximab at the initial presentation and continued to respond to rituximab during subsequent flares over the subsequent 5 years.

Original languageEnglish (US)
Pages (from-to)E5-E7
JournalCutis
Volume103
Issue number6
Publication statusPublished - Jan 1 2019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Lowe, C. D., Brahe, C. A., Green, B. P., Lam, T. K., & Meyerle, J. H. (2019). Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis, 103(6), E5-E7.